These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 1225988)

  • 1. Central adrenergic neurons in DOCA-salt hypertension.
    Lamprecht F; Jacobowitz DM; Richardson JS; Kopin IJ
    J Neurosci Res; 1975; 1(3-4):227-34. PubMed ID: 1225988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of intraventricular and intraspinal 6-hydroxydopamine on blood pressure of DOCA-saline hypertensive rats.
    Kubo T; Hashimoto M
    Arch Int Pharmacodyn Ther; 1979 Mar; 238(1):50-9. PubMed ID: 485704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the effects of intracranial injections of 6-OHDA and guanethidine on consummatory behavior and monoamine depletion.
    Singer G; Armstrong S; Evans B; Burnstock G
    Pharmacol Biochem Behav; 1975; 3(1 Suppl):91-106. PubMed ID: 1226403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of chronic intracranial injection of low and high concentrations of guanethidine in the rat.
    Evans BK; Singer G; Armstrong S; Saunders PE; Burnstock G
    Pharmacol Biochem Behav; 1975; 3(2):219-28. PubMed ID: 1096174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebral intraventricular 6-hydroxydopamine prevents vascular changes in the mineralocorticoid hypertensive rat.
    Mecca TE; Lamb FS; Hall JL; Webb RC
    Proc Soc Exp Biol Med; 1985 Jun; 179(2):248-53. PubMed ID: 3921975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Origin of various enzymes released from the substantia nigra and caudate nucleus: effects of 6-hydroxydopamine lesions of the nigro-striatal pathway.
    Greenfield SA; Grünewald RA; Foley P; Shaw SG
    J Comp Neurol; 1983 Feb; 214(1):87-92. PubMed ID: 6404955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Catecholamine synapses and contents in the paraventricular hypothalamic nucleus and nucleus tractus solitarius of DOCA-salt hypertensive rats.
    Hwang BH; Chiueh CC; Severs WB
    Anat Rec; 1984 Aug; 209(4):553-63. PubMed ID: 6476421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic treatment with mianserin prevents DOCA-salt hypertension in rats--evidence for the involvement of central 5-HT2 receptors.
    Silva AL; Cabral AM; Abreu GR; Pires JG; Bissoli NS; Ramage AG
    Eur J Pharmacol; 2005 Aug; 518(2-3):152-7. PubMed ID: 16014306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Self-injurious behavior and dopaminergic neuron system in neonatal 6-hydroxydopamine-lesioned rat: 2. Intracerebral microinjection of dopamine agonists and antagonists.
    Okamura H; Murakami T; Yokoyama C; Nakamura T; Ibata Y
    J Pharmacol Exp Ther; 1997 Feb; 280(2):1031-7. PubMed ID: 9023320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Injection of 6-hydroxydopamine in the substantia nigra of the rat. I. Morphological study.
    Sotelo C; Javoy F; Agid Y; Glowinski J
    Brain Res; 1973 Aug; 58(2):269-90. PubMed ID: 4756130
    [No Abstract]   [Full Text] [Related]  

  • 11. KDI tripeptide of gamma1 laminin protects rat dopaminergic neurons from 6-OHDA induced toxicity.
    Väänänen AJ; Rauhala P; Tuominen RK; Liesi P
    J Neurosci Res; 2006 Aug; 84(3):655-65. PubMed ID: 16810683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 6-hydroxydopamine destruction of central adrenergic neurones prevents or reverses developing DOCA-salt hypertension in rats.
    Lamprecht F; Richardson JS; Williams RB; Kopin IJ
    J Neural Transm; 1977; 40(2):149-58. PubMed ID: 323422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of DOCA saline hypertension by central 6-hydroxydopamine: role of saline intake.
    Dargie HJ; Dollery CT; Lewis PJ
    Br J Pharmacol; 1975 Mar; 53(3):455P. PubMed ID: 1137753
    [No Abstract]   [Full Text] [Related]  

  • 14. Demonstration of the nigrostriatal projection by silver staining after nigral injections of 6-hydroxydopamine.
    Maler L; Fibiger HC; McGeer PL
    Exp Neurol; 1973 Aug; 40(2):505-15. PubMed ID: 4125858
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of 6-hydroxydopamine on the nature of proteins undergoing axoplasmic transport in nigro-neostriatal neurons.
    Singh VK; Fibiger HC; McGeer PL
    J Neurochem; 1974 Sep; 23(3):601-4. PubMed ID: 4153672
    [No Abstract]   [Full Text] [Related]  

  • 16. Intracranial injection of drugs: comparison of diffusion of 6-OHDA and guanethidine.
    Evans BK; Armstrong S; Singer G; Cook RD; Burnstock G
    Pharmacol Biochem Behav; 1975; 3(2):205-28. PubMed ID: 1096173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective catecholamine depletion of structures along the ventral lamina terminalis: effects on experimentally-induced drinking and pressor responses.
    Bellin SI; Landas SK; Johnson AK
    Brain Res; 1988 Jul; 456(1):9-16. PubMed ID: 3136861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different behavioral responses to L-DOPA after anterolateral or posterolateral hypothalamic injections of 6-hydroxydopamine.
    Ervin GN; Fink JS; Young RC; Smith GP
    Brain Res; 1977 Sep; 132(3):507-20. PubMed ID: 303138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of catecholamine in the effects of trauma on thermoregulation, studied in rats treated with 6-hydroxydopamine.
    Stoner HB
    Br J Exp Pathol; 1977 Feb; 58(1):42-9. PubMed ID: 836766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Degenerative processes after punctate intracerebral administration of 6-hydroxydopamine.
    Butcher LL
    J Neural Transm; 1975; 37(3):189-203. PubMed ID: 1185165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.